Andere Sprachen Rallybio Corporation

Aktien

A3CWDP

US75120L1008

RLYB

Realtime-Estimate Cboe BZX Andere Börsenplätze 18:57:00 06.05.2024			% 5 Tage	% 1. Jan.
1,93 ^USD	+5,46 %		+2,70 %	-20,50 %

17.04.	Ralebio Corporation kündigt die Präsentation der Ergebnisse einer systematischen Literaturübersicht und Meta-Analyse zu FNAIT auf der Jahrestagung 2024 der Academy of Managed Care Pharmacy an	CI
12.04.	Die größten Verlierer der Vorbörse	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting	17.04.
Ralebio Corporation Announces the Presentation of Results from FNAIT Systematic Literature Review and Meta- Analysis At the Academy of Managed Care Pharmacy 2024 Annual Meeting	17.04.
Key Stocks to Watch: Recent News, Developments and Market Potential KAVL, INBS, GEVI, VTAK, RLYB	15.04.
Top Premarket Decliners	12.04.
US Equity Markets Close Mixed After March Producer Price Inflation Data	11.04.
Sector Update: Health Care Stocks Softer Late Afternoon	11.04.
Top Midday Gainers	11.04.
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Ahead of Another Key Inflation Report	11.04.
Top Premarket Gainers	11.04.
Rallybio Corporation Announces Collaboration with Johnson & Johnson	10.04.
Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)	10.04.
Rallybio Corporation announced that it has received $6.599999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.	10.04.
Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting	01.04.
Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results	12.03.
Rallybio Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	12.03.
Rallybio Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	12.03.
North American Morning Briefing : Stock Futures -2-	11.03.
Rallybio to Present at the TD Cowen 44th Annual Health Care Conference	26.02.
North American Morning Briefing : S&P 500 to Open -2-	08.02.
Rallybio Corporation Announces the Prioritization of Its Portfolio and a 45% Workforce Reduction to Focus Resources on Its Phase 2-Ready Clinical Stage Programs	06.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Rallybio Corporation

Aktien

A3CWDP

US75120L1008

RLYB

Andere Sprachen

Filter